The metabolism andriol cycle of olanzapine may vary under the influence of inhibitors or inducers of cytochromedeca durabolin dosage isoenzymes, exhibiting a specific activity against isozyme . CO increased in smokers and in patients taking carbamazepine (due to the increased activity of the isoenzyme.
Known potential inhibitors of isoenzyme can decrease the DA. Olanzapine is not a potential inhibitor of isozyme , therefore olanzapine pharmacokinetics of drugs such as theophylline, which is metabolized primarily involving isoenzyme , does not change.
Fluvoxamine, a specific inhibitor of isozyme, significantly alters the pharmacokinetics of olanzapine, increasing its Cmax 54% of women in non-smokers and 77% in male smokers with increasing values of the area under the concentration-time curve by 52% and 108%, respectively. It is necessary to reduce the dose of olanzapine in patients taking fluvoxamine or other inhibitors of isoenzyme CYP1A2, such as ciprofloxacin.
A single dose of olanzapine therapy following medications: imipramine or its metabolite desipramine was not accompanied by the suppression of their metabolism. . There was no evidence of drug interactions and olanzapine together with lithium or biperidenom
A single dose of aluminum and magnesium antacid or cimetidine did not affect the bioavailability of olanzapine by ingestion. Simultaneous administration of activated charcoal reduces the bioavailability of olanzapine by 50-60%.
Fluoxetine (60 mg or 60 mg once daily for 8 days) causes an increase in Cmax of olanzapine average 16% decrease in CO and an average of 16%. The degree of influence of fluoxetine significantly inferior to the severity of individual differences in pharmacokinetic parameters, so it is usually not recommended to change the dose of olanzapine when used in combination with fluoxetine.
In in vitro studies using human liver microsomes have shown that olanzapine significantly suppresses the formation of glucuronide valproic acid (the main path valproic acid metabolism). Valproic acid is also significantly affect the metabolism of olanzapine. Therefore, clinically significant pharmacokinetic interaction between olanzapine and valproate is unlikely.
On the background of a stable concentration of olanzapine pharmacokinetics of ethanol changes were noted. However, reception of ethanol with olanzapine may be associated with increased pharmacological effects of olanzapine, such as sedation. Caution should be exercised when olanzapine in patients who consume alcohol or taking drugs that may cause depression of the central nervous system.
The simultaneous use of olanzapine with antiparkinsonian drugs in patients with dementia in disease patients is not recommended. As with andriol cycle deca durabolin dosage other antipsychotic drugs, olanzapine should be careful while the use of drugs that prolong the QT interval.
Cautions Neuroleptic malignant syndrome. When using any antipsychotic drugs, including olanzapine, may develop CSN, the clinical manifestations of which include a significant increase in body temperature, muscle rigidity, altered mental status, and autonomic disorders (tachycardia, unstable pulse or blood pressure, cardiac arrhythmia, increased sweating ). Additional signs may include increasing the concentration of serum CK, myoglobinuria (rhabdomyolysis symptom), and acute renal failure. Clinical manifestations of neuroleptic malignant syndrome or a significant increase in body temperature with no other symptoms of this syndrome require discontinuation of all antipsychotics, including olanzapine. Parkinson’s disease. Use of the drug Olanzapine -Teva not recommended for the treatment of psychosis in Parkinson’s disease, caused by the use of dopamine receptor agonists in connection with the that can worsen the symptoms of Parkinson’s disease and hallucinations. The efficacy of olanzapine for the treatment of psychotic symptoms in this case does not exceed the use of a placebo. Psychosis associated with dementia, and / or behavioral disorders. The drug deca durabolin dosage not recommended for use in elderly patients with psychosis associated with dementia and / or violations behavior, due to the fact that in this group of patients reported an increase risk of cerebrovascular disorders (stroke, transient ischemic attack) and death. It was found that the high mortality had no connection with olanzapine dose or duration of treatment with olanzapine. Risk factors that may predispose patients to increased mortality in this population is older than 65 years, dysphagia, sedation, malnutrition, dehydration, lung diseases (pneumonia with / without aspiration), or the simultaneous use of benzodiazepines. In addition, it found that all the patients who have been reported cerebrovascular disorders, as well as in the group of patients taking olanzapine and placebo suffered vascular dementia or dementia of mixed type. The efficacy of olanzapine in this group of patients was andriol cycle not determined.